Pravin S. Iyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pravin S. Iyer has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Manoranjan Panda
2 shared publicationsAshwini Narayan
Department of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India
1 shared publicationGayathri Balakrishnan
Department of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India
1 shared publicationGopinath Gorai
Department of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India
1 shared publicationJyothi Bhat
Department of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India
1 shared publicationLalit Kumar Jena
Department of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India
1 shared publication
Latest Publications
- 4 March 2016
- Published by Wiley in Methods and Principles in Medicinal Chemistry
- p. 747-760
A Fragmentation Enumeration Approach to Generating Novel Drug Leads
- 4 March 2016
- Published by Wiley in Methods and Principles in Medicinal Chemistry
- p. 747-760
A Fragmentation Enumeration Approach to Generating Novel Drug Leads
- 21 July 2014
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 5 (9) , 1005-1009
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis
A cellular activity-based screen on Mycobacterium tuberculosis (Mtb) H37Rv using a focused library from the AstraZeneca corporate collection led to the identification of 2-phenylindoles and arylsulphonamides, novel antimycobacterial scaffolds. Both the series were bactericidal in vitro and in an intracellular macrophage infection model, active against drug sensitive and drug resistant Mtb clinical isolates, and specific to mycobacteria. The scaffolds showed promising structure–activity relationships; compounds with submicromolar cellular potency were identified during the hit to lead exploration. Furthermore, compounds from both scaffolds were tested for inhibition of known target enzymes or pathways of antimycobacterial drugs including InhA, RNA polymerase, DprE1, topoisomerases, protein synthesis, and oxidative-phosphorylation. Compounds did not inhibit any of the targets suggesting the potential of a possible novel mode of action(s). Hence, both scaffolds provide the opportunity to be developed further as leads and tool compounds to uncover novel mechanisms for tuberculosis drug discovery.
- 21 July 2014
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 5 (9) , 1005-1009
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis
A cellular activity-based screen on Mycobacterium tuberculosis (Mtb) H37Rv using a focused library from the AstraZeneca corporate collection led to the identification of 2-phenylindoles and arylsulphonamides, novel antimycobacterial scaffolds. Both the series were bactericidal in vitro and in an intracellular macrophage infection model, active against drug sensitive and drug resistant Mtb clinical isolates, and specific to mycobacteria. The scaffolds showed promising structure–activity relationships; compounds with submicromolar cellular potency were identified during the hit to lead exploration. Furthermore, compounds from both scaffolds were tested for inhibition of known target enzymes or pathways of antimycobacterial drugs including InhA, RNA polymerase, DprE1, topoisomerases, protein synthesis, and oxidative-phosphorylation. Compounds did not inhibit any of the targets suggesting the potential of a possible novel mode of action(s). Hence, both scaffolds provide the opportunity to be developed further as leads and tool compounds to uncover novel mechanisms for tuberculosis drug discovery.
- 1 January 2014
- Published by Elsevier
- p. 209-220
Advancement of Cell Wall Inhibitors in Mycobacterium tuberculosis*Present address: Sai Life Sciences Ltd, Pune, India.
- 1 January 2014
- Published by Elsevier
- p. 209-220
Advancement of Cell Wall Inhibitors in Mycobacterium tuberculosis*Present address: Sai Life Sciences Ltd, Pune, India.